All Oncology News

Bone metastases in castration-resistant prostate cancer create a significant problem, and a rising incidence of men are developing advanced disease.

Maura Dickler, MD, discusses findings from the recent phase II study exploring abemaciclib as a single agent in patients with HR-positive breast cancer, along with an upcoming phase III trial looking at combination strategies.

The European Commission has approved brentuximab vedotin (Adcetris) for use as a consolidation therapy following autologous stem cell transplantation in patients with CD30-positive Hodgkin lymphoma at risk of relapse or progression.

Joanne L. Blum, MD, PhD, discusses the design and phase III results from the ABC trials, and what impact the encouraging findings could have in patients with HER2-negative breast cancer.

The shockwaves created by the UK's vote to secede from the European Union are likely to reverberate for years to come, particularly in the field of oncology.

The European Commission has approved carfilzomib in combination with dexamethasone for adult patients with multiple myeloma who have received at least one prior therapy.

A new drug application has been submitted for binimetinib as a potential treatment for patients with advanced NRAS-mutant metastatic melanoma.

Reinhard Georg Dummer, MD, shares the encouraging phase III findings from the NEMO trial and how it shakes up the treatment paradigm for patients with NRAS-mutated melanoma.

The FDA has granted a breakthrough therapy designation to ibrutinib has a potential treatment for patients with chronic graft-versus-host-disease after failure of one or more lines of systemic therapy.

A phase III trial investigating the first-in-class immunotherapy vaccine nelipepimut-S (NeuVax) for the prevention of recurrence in early-stage breast cancer has been stopped due to futility.

A year after announcing its intention to launch the Oncology Care Model alternative payment plan for oncology care, The Centers for Medicare & Medicaid Services said it has 196 practices enrolled across the United States and that the official start date is Friday, July 1.

Richard Pazdur, MD, has been named the acting director of the FDA's newly created Oncology Center of Excellence, which is aimed to expedite the development of novel combination products and support an integrated approach to oncology research.

Maintenance therapy with niraparib improved progression-free survival compared with placebo for patients with recurrent ovarian cancer harboring a germline BRCA mutation or homologous recombination deficiency.

Members of the Pediatric Subcommittee of the FDA's Oncologic Drugs Advisory Committee voiced their support for new clinical trials examining promising cancer agents in pediatric patients.

The FDA has granted an orphan drug designation to the STAT3 targeted agent napabucasin as a treatment for patients with gastric and gastroesophageal junction cancer.

Potential to render cancer cells less able to cope with hypoxia.

Ranee Mehra, MD, discusses what the KEYNOTE-012 findings could mean for patients, the growing role for the immunotherapy agent in head and neck cancer, and what else is on the horizon for the treatment landscape.

A marketing authorization application has been submitted to the European Medicines Agency for neratinib as a potential extended adjuvant therapy for patients with HER2-positive early stage breast cancer following 12 months of trastuzumab.

The EMA's Committee for Medicinal Products for Human Use has granted a positive opinion for use of pembrolizumab (Keytruda) as a treatment for patients with locally advanced or metastatic PD-L1-positive non–small cell lung cancer.

The FDA has granted nivolumab (Opdivo) a breakthrough therapy designation for the treatment of patients with unresectable locally advanced or metastatic urothelial carcinoma after the failure of a platinum-containing regimen.

The FDA has granted a priority review designation to Lutathera (177Lutetium DOTA-octreotate) as a treatment for patients with gastroenteropancreatic neuroendocrine tumors.

Morganna Freeman, DO, explains the impact of hedgehog inhibitors in basal cell carcinoma, the ideal patient to receive them, and emerging agents on the horizon for treatment of the disease.

The FDA has granted a breakthrough therapy designation to ruxolitinib for the treatment of patients with acute graft-versus-host disease.

Ryan J. Sullivan, MD, discusses which patients are at risk for advanced basal cell carcinoma, current standard therapies, and options for those who relapse after treatment with hedgehog/smoothened inhibitors.

At a time when PD-1 inhibitors are dominating the immunotherapy field, a team of researchers is seeking to use groundbreaking CRISPR gene editing technology for the first time in human beings to create an engineered T-cell agent that would knock out the gene that controls the immune checkpoint’s activity.

Francesco Forconi, MD, discusses his research into the B-cell receptor structure and its function in chronic lymphocytic leukemia.

The EMA’s Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion to ofatumumab regarding its potential use in the maintenance setting for patients with relapsed chronic lymphocytic leukemia.

OncLive, a leading provider of news, resources and information to oncology professionals, has entered into a collaborative agreement with the European CanCer Organisation (ECCO), the united voice of European cancer professionals, to deliver engaging oncological clinical and patient-focused content to audiences throughout the United States and Europe.

Michael J. Overman, MD, discusses the findings of the phase II CheckMate-142 study, which examined nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with high microsatellite instability colorectal cancer.

Howard A. "Skip" Burris, MD, offers insight on patient-reported outcomes from the MARIANNE trial and highlights exciting advancements in the neoadjuvant landscape of HER2-positive breast cancer.